SA521421882B1 - نظم، وطرق وجهاز لتمديد مجموعة من الخلايا - Google Patents

نظم، وطرق وجهاز لتمديد مجموعة من الخلايا

Info

Publication number
SA521421882B1
SA521421882B1 SA521421882A SA521421882A SA521421882B1 SA 521421882 B1 SA521421882 B1 SA 521421882B1 SA 521421882 A SA521421882 A SA 521421882A SA 521421882 A SA521421882 A SA 521421882A SA 521421882 B1 SA521421882 B1 SA 521421882B1
Authority
SA
Saudi Arabia
Prior art keywords
cells
population
expanding
kits
methods
Prior art date
Application number
SA521421882A
Other languages
Arabic (ar)
English (en)
Inventor
ستيمبيرجير كريستيان
جيرميروث لوثار
Original Assignee
جونو ثيرابيوتكس جي إم بي اتش
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by جونو ثيرابيوتكس جي إم بي اتش filed Critical جونو ثيرابيوتكس جي إم بي اتش
Publication of SA521421882B1 publication Critical patent/SA521421882B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/48—Automatic or computerized control
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2537/00—Supports and/or coatings for cell culture characterised by physical or chemical treatment
    • C12N2537/10—Cross-linking

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Sustainable Development (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Computer Hardware Design (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
SA521421882A 2014-04-16 2016-10-16 نظم، وطرق وجهاز لتمديد مجموعة من الخلايا SA521421882B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980506P 2014-04-16 2014-04-16
PCT/EP2015/058339 WO2015158868A2 (en) 2014-04-16 2015-04-16 Methods, kits and apparatus for expanding a population of cells

Publications (1)

Publication Number Publication Date
SA521421882B1 true SA521421882B1 (ar) 2023-11-19

Family

ID=53052805

Family Applications (3)

Application Number Title Priority Date Filing Date
SA521421882A SA521421882B1 (ar) 2014-04-16 2016-10-16 نظم، وطرق وجهاز لتمديد مجموعة من الخلايا
SA516380090A SA516380090B1 (ar) 2014-04-16 2016-10-16 نظم، وطرق وجهاز لتمديد مجموعة من الخلايا
SA520412247A SA520412247B1 (ar) 2014-04-16 2016-10-16 نظم، وطرق وجهاز لتمديد مجموعة من الخلايا

Family Applications After (2)

Application Number Title Priority Date Filing Date
SA516380090A SA516380090B1 (ar) 2014-04-16 2016-10-16 نظم، وطرق وجهاز لتمديد مجموعة من الخلايا
SA520412247A SA520412247B1 (ar) 2014-04-16 2016-10-16 نظم، وطرق وجهاز لتمديد مجموعة من الخلايا

Country Status (27)

Country Link
US (2) US11274278B2 (enExample)
EP (2) EP3132247B1 (enExample)
JP (4) JP6696969B2 (enExample)
KR (2) KR102714469B1 (enExample)
CN (3) CN116656605A (enExample)
AU (2) AU2015248786B2 (enExample)
BR (1) BR112016024072B1 (enExample)
CA (2) CA2945889C (enExample)
CY (1) CY1124717T1 (enExample)
DK (1) DK3132247T3 (enExample)
ES (1) ES2892927T3 (enExample)
HR (1) HRP20211430T1 (enExample)
HU (1) HUE056852T2 (enExample)
IL (3) IL293587B2 (enExample)
LT (1) LT3132247T (enExample)
MX (2) MX380519B (enExample)
MY (1) MY184699A (enExample)
PH (2) PH12016502017B1 (enExample)
PL (1) PL3132247T3 (enExample)
PT (1) PT3132247T (enExample)
RS (1) RS62471B1 (enExample)
RU (2) RU2020133435A (enExample)
SA (3) SA521421882B1 (enExample)
SG (2) SG10201808491UA (enExample)
SI (1) SI3132247T1 (enExample)
SM (1) SMT202100600T1 (enExample)
WO (1) WO2015158868A2 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013124474A2 (en) 2012-02-23 2013-08-29 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP3132247B1 (en) 2014-04-16 2021-08-18 Juno Therapeutics GmbH Methods, kits and apparatus for expanding a population of cells
ES2995052T3 (en) 2014-04-23 2025-02-05 Juno Therapeutics Inc Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
EP3365678A1 (en) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods for culturing cells and kits and apparatus for same
IL258844B2 (en) 2015-10-22 2024-03-01 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
EP3365453A2 (en) * 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods, kits, agents and apparatuses for transduction
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
CN107129988A (zh) * 2016-02-29 2017-09-05 广西医科大学 一种特异性结合cd3的核酸适配体及其筛选方法和应用
AU2017272349B2 (en) * 2016-06-02 2022-12-01 Klotho Therapeutics, Inc. Therapeutic recombinant klotho proteins and compositions and methods involving the same
MA45784A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
BR112019011207A2 (pt) * 2016-12-05 2019-10-08 Juno Therapeutics Inc produção de células modificadas para terapia celular adotiva
US12234441B2 (en) * 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) * 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) * 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP4647493A3 (en) * 2017-04-27 2026-01-14 Juno Therapeutics, Inc. Oligomeric particle reagents and methods of use thereof
WO2019089855A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
AU2018379091A1 (en) 2017-12-08 2020-06-25 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
KR102847676B1 (ko) * 2017-12-15 2025-08-21 알레타 바이오쎄라퓨틱스, 인크. Cd19 변이체
CN107904278B (zh) * 2017-12-25 2021-07-20 北昊干细胞与再生医学研究院有限公司 检测药物对细胞增殖影响的方法
US11149244B2 (en) * 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
EP3790958A1 (en) * 2018-05-08 2021-03-17 Life Technologies Corporation Compositions and methods for culturing and expanding cells
US20210206857A1 (en) * 2018-05-21 2021-07-08 Bioprocessia Technologies Llc Multivalent protein complexes
CA3108657A1 (en) * 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
EP3623383A1 (en) 2018-09-11 2020-03-18 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved bispecific flt3xcd3 antigen binding proteins
US12195543B2 (en) 2018-09-11 2025-01-14 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Anti-FLT3 antigen binding proteins
SG11202102986XA (en) * 2018-09-24 2021-04-29 Southwest Res Inst Three-dimensional bioreactors
US12522660B2 (en) 2018-10-31 2026-01-13 C3S2 Gmbh Methods for selection and stimulation of cells and apparatus for same
KR20200132147A (ko) * 2019-05-15 2020-11-25 의료법인 성광의료재단 자연 살해 세포의 배양용 조성물 및 이를 이용한 방법
EP3978925A4 (en) * 2019-05-24 2023-06-28 Sol Bio Corporation Affinity separation system and method using switch-like adhesion reaction
CA3139965A1 (en) * 2019-06-07 2020-12-10 Ivie AIFUWA Automated t cell culture
IL292319B2 (en) 2019-10-30 2026-01-01 C3S2 Gmbh Cell selection and/or stimulation devices and methods of use
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
CN115335399A (zh) 2019-12-06 2022-11-11 朱诺治疗学股份有限公司 针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
IL293430A (en) 2019-12-06 2022-07-01 Juno Therapeutics Inc Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
US11965882B2 (en) 2020-01-31 2024-04-23 Cell.Copedia GmbH Methods of isolating a biological entity
MX2022009830A (es) 2020-02-12 2022-10-28 Juno Therapeutics Inc Composiciones de celulas t que expresan receptores de antigenos quimericos dirigidos a bcma y metodos y usos de las mismas.
IL295384A (en) 2020-02-12 2022-10-01 Juno Therapeutics Inc Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
US12241086B2 (en) 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
US20230324408A1 (en) 2020-08-05 2023-10-12 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
CA3210581A1 (en) 2021-03-22 2022-09-29 Neil HAIG Methods of determining potency of a therapeutic cell composition
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
EP4373920A1 (en) 2021-07-19 2024-05-29 Repairon Immuno GmbH Method of producing a population of immune cells from pluripotent stem cells
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
JP2026501122A (ja) 2022-12-09 2026-01-14 ジュノー セラピューティクス インコーポレイテッド ホログラフィックイメージングを使用して細胞表現型を予測するための機械学習方法
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
CN121127253A (zh) 2023-02-28 2025-12-12 朱诺治疗学股份有限公司 治疗系统性自身免疫性疾病的细胞疗法
CN121311765A (zh) 2023-04-18 2026-01-09 朱诺治疗学股份有限公司 评估治疗性细胞组合物的效力的细胞毒性测定
KR20260026101A (ko) 2023-05-23 2026-02-25 주노 쎄러퓨티크스 인코퍼레이티드 T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법
CN117448255B (zh) * 2023-09-28 2024-12-31 深圳市龙华区人民医院 S2饲养细胞、制备方法及其应用
WO2025109111A1 (en) * 2023-11-22 2025-05-30 Immudex Aps Immune cell activating multimers
KR102824339B1 (ko) * 2024-07-01 2025-06-26 현대자동차주식회사 배터리 제어 장치 및 그 방법
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
US20260061053A1 (en) 2024-08-28 2026-03-05 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
JP2624470B2 (ja) 1984-10-02 1997-06-25 バイオジェン インコーポレイテッド ストレプトアビジン様ポリペプチドの製造
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
DK0700430T3 (da) 1993-06-04 2005-08-15 Us Navy Fremgangsmåder til selektivt af stimulere proliferation af T-celler
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
JPH11501008A (ja) 1995-02-09 1999-01-26 ユニバーシティ オブ ワシントン 改変−アフィニティーストレプトアビジン
WO1997011183A1 (en) 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
EP0977770A4 (en) 1997-03-14 2000-04-05 Univ Boston DIFFERENTLY FLAVORED STREPTAVIDINE
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
US6664042B1 (en) 1999-01-26 2003-12-16 Cornell Research Foundation, Inc. Determining viral load in double negative T cells
WO2000046240A2 (en) * 1999-02-03 2000-08-10 Amgen Inc. Polypeptides involved in immune response
MXPA01007820A (es) 1999-02-04 2003-06-19 Technion Res & Dev Foundation Metodo y aparato para mantenimiento y expansion de celulas de tallo hemopoyeticas y/o celulas progenitoras.
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2003074546A2 (de) 2002-03-01 2003-09-12 Erdmann Volker A Streptavidin-bindungspeptid
US7754155B2 (en) 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
AU2003234194A1 (en) 2002-04-23 2003-11-10 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
ES2375724T3 (es) 2002-09-27 2012-03-05 The General Hospital Corporation Dispositivo microflu�?dico para seperación de células y sus usos.
JP2006525013A (ja) 2003-05-02 2006-11-09 インセプション バイオサイエンス インコーポレイティッド 血液幹細胞の数の増幅のための装置および方法
DK1623017T3 (da) * 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
JP2007512528A (ja) 2003-11-20 2007-05-17 バイオセンサー、アプリケーションズ、スエーデン、アクチボラグ 所定の抗原混合物に特異的な少なくとも２種類の異なる抗体の混合物およびその混合物の使用
SE0400181D0 (sv) 2004-01-29 2004-01-29 Gyros Ab Segmented porous and preloaded microscale devices
DK1766400T3 (da) 2004-06-03 2009-07-20 Meso Scale Technologies Llc Fremgangsmåde til at udföre fuldblodsanalyser
DK1800136T3 (da) 2004-10-15 2012-03-26 Danisco Us Inc Kompetitiv differentiel screening
WO2006058226A2 (en) * 2004-11-24 2006-06-01 The Trustees Of Boston University Modified dimeric streptavidins and uses thereof
US20060252087A1 (en) 2005-01-18 2006-11-09 Biocept, Inc. Recovery of rare cells using a microchannel apparatus with patterned posts
US7704708B2 (en) * 2006-02-13 2010-04-27 Uti Limited Partnership Monomeric streptavidin muteins
US7855057B2 (en) 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
WO2007117602A2 (en) 2006-04-07 2007-10-18 Biogen Idec Ma Inc. Isolation and use of human regulatory t cells
US20070238169A1 (en) * 2006-04-11 2007-10-11 The Board Of Trustees Of The Leland Stanford Junior University Cell sorter and culture system
US20080085532A1 (en) 2006-09-18 2008-04-10 Jorn Gorlach Method for determining the immune status of a subject
BRPI0717651A2 (pt) 2006-10-17 2013-12-24 Oncotherapy Science Inc Vacinas de peptídeo para cânceres que expressam polipeptídeos mphosph1 ou depdc1
WO2008053973A1 (fr) 2006-11-02 2008-05-08 Kyowa Medex Co., Ltd. Procédé d'essai immunologique d'un composant à mesurer
EP2518193A3 (en) 2006-11-15 2013-01-23 Invitrogen Dynal AS Methods for reversibly binding a biotin compound to a support
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
CN101226118B (zh) 2007-01-19 2010-06-16 中国医学科学院肿瘤研究所 一种兼容免疫荧光分析的细胞化学染色方法及其用途
EP2137308B1 (en) * 2007-03-26 2016-08-03 Agenus Inc. Cell surface display, screening and production of proteins of interest
WO2009003493A2 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
PT2193199E (pt) 2007-08-20 2014-02-14 Nextera As Apresentação em fagos por intermédio de pvii
DK2433713T3 (en) 2007-12-07 2017-09-25 Miltenyi Biotec Gmbh CELL PROCESSING SYSTEMS AND PROCEDURES
KR20180090396A (ko) 2008-01-18 2018-08-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법
EP2245142B1 (en) 2008-01-29 2018-03-07 Fred Hutchinson Cancer Research Center Identification of cd8+ t cells that are cd161hi and/or il18r(alpha)hi and have rapid drug efflux capacity
CN101446576B (zh) 2008-12-29 2011-06-22 江苏省苏微微生物研究有限公司 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法
WO2010080032A2 (en) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
US20110070581A1 (en) 2009-04-27 2011-03-24 Amit Gupta Separation of Leukocytes
US20120214187A1 (en) * 2009-11-02 2012-08-23 Ffina Biolutions, Llc Method for Enhancing the Sensitivity of Antibody Based Assays
US20120321665A1 (en) * 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
EP2363501A1 (en) 2010-03-02 2011-09-07 Universitätsklinikum Hamburg-Eppendorf Method for isolating target cells
WO2012017081A1 (en) 2010-08-06 2012-02-09 Ludwig-Maximilians-Universität München Identification of t cell target antigens
WO2012058627A2 (en) 2010-10-29 2012-05-03 Miqin Zhang Pre-targeted nanoparticle system and method for labeling biological particles
RU2688185C2 (ru) 2011-03-23 2019-05-21 Фред Хатчинсон Кэнсер Рисерч Сентер Способ и композиции для клеточной иммунотерапии
PT2734538T (pt) * 2011-07-18 2018-08-02 Iba Gmbh Processo para corar, de forma reversível, uma célula-alvo
US9353161B2 (en) 2011-09-13 2016-05-31 Uti Limited Partnership Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins
WO2013124474A2 (en) 2012-02-23 2013-08-29 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
UA114108C2 (uk) * 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
CN112375846A (zh) 2012-07-13 2021-02-19 宾夕法尼亚大学董事会 评估用于施用的转导t细胞的适用性的方法
KR102264290B1 (ko) 2012-08-20 2021-06-10 프레드 헛친슨 켄서 리서치 센터 세포 면역요법을 위한 방법 및 조성물
EP2920204B1 (en) 2012-11-16 2019-09-18 IBA GmbH Streptavidin muteins and methods of using them
CN103305464B (zh) 2013-06-05 2015-04-15 南昌大学 直接分离cd4+和cd8+淋巴细胞的方法
US9698876B2 (en) 2013-07-23 2017-07-04 Telefonaktiebolaget Lm Ericsson (Publ) Transmission mode allocation in LTE networks
SG11201605046YA (en) 2013-12-20 2016-07-28 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof
SI3888674T1 (sl) 2014-04-07 2024-08-30 Novartis Ag Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
EP3132247B1 (en) * 2014-04-16 2021-08-18 Juno Therapeutics GmbH Methods, kits and apparatus for expanding a population of cells
ES2995052T3 (en) 2014-04-23 2025-02-05 Juno Therapeutics Inc Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
JP6661544B2 (ja) 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したｔ細胞の自動生成法
CA2946552A1 (en) 2014-04-25 2015-10-29 Bluebird Bio, Inc. Improved methods for manufacturing adoptive cell therapies
CA2945414C (en) * 2014-04-30 2023-05-09 Iba Gmbh Method of isolating a target cell
IL303972A (en) 2015-04-08 2023-08-01 Novartis Ag CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
IL258844B2 (en) 2015-10-22 2024-03-01 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
EP3365453A2 (en) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods, kits, agents and apparatuses for transduction
EP3365678A1 (en) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods for culturing cells and kits and apparatus for same
AU2016363025B2 (en) 2015-12-03 2021-04-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
EP4647493A3 (en) 2017-04-27 2026-01-14 Juno Therapeutics, Inc. Oligomeric particle reagents and methods of use thereof
CA3108657A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
US12522660B2 (en) 2018-10-31 2026-01-13 C3S2 Gmbh Methods for selection and stimulation of cells and apparatus for same

Also Published As

Publication number Publication date
IL248360A0 (en) 2016-11-30
IL280738A (en) 2021-03-25
IL293587B1 (en) 2024-10-01
IL280738B (en) 2022-07-01
PH12020551028A1 (en) 2021-06-07
PL3132247T3 (pl) 2022-01-03
HRP20211430T1 (hr) 2021-12-10
AU2015248786B2 (en) 2021-11-04
KR20220150988A (ko) 2022-11-11
US20220195388A1 (en) 2022-06-23
RS62471B1 (sr) 2021-11-30
SMT202100600T1 (it) 2021-11-12
IL248360B (en) 2021-02-28
CA2945889C (en) 2024-01-09
JP2025060756A (ja) 2025-04-10
AU2022200527B2 (en) 2025-03-27
MX380519B (es) 2025-03-12
CN116656605A (zh) 2023-08-29
KR102459384B1 (ko) 2022-10-26
SA520412247B1 (ar) 2023-12-05
SG11201608557UA (en) 2016-11-29
EP3132247A2 (en) 2017-02-22
RU2020133435A (ru) 2020-12-01
CA2945889A1 (en) 2015-10-22
WO2015158868A3 (en) 2016-01-28
EP3988920A1 (en) 2022-04-27
US20170037368A1 (en) 2017-02-09
RU2735640C2 (ru) 2020-11-05
JP2017513524A (ja) 2017-06-01
CA3176848A1 (en) 2015-10-22
CN106414724A (zh) 2017-02-15
JP2020124210A (ja) 2020-08-20
AU2015248786A1 (en) 2016-11-03
NZ763585A (en) 2021-10-29
ES2892927T3 (es) 2022-02-07
RU2016144724A3 (enExample) 2018-12-12
JP2023062124A (ja) 2023-05-02
SA516380090B1 (ar) 2021-10-21
LT3132247T (lt) 2021-12-10
JP7762499B2 (ja) 2025-10-30
MX2016013493A (es) 2017-05-10
SG10201808491UA (en) 2018-11-29
PH12016502017A1 (en) 2017-01-09
KR102714469B1 (ko) 2024-10-11
MY184699A (en) 2021-04-18
NZ725213A (en) 2021-10-29
EP3132247B1 (en) 2021-08-18
DK3132247T3 (da) 2021-10-11
BR112016024072A2 (pt) 2017-10-10
US11274278B2 (en) 2022-03-15
KR20170003932A (ko) 2017-01-10
SI3132247T1 (sl) 2021-12-31
CY1124717T1 (el) 2022-07-22
NZ763583A (en) 2021-10-29
RU2735640C9 (ru) 2021-02-08
BR112016024072B1 (pt) 2021-02-09
CN111961647A (zh) 2020-11-20
PH12016502017B1 (en) 2017-01-09
JP6696969B2 (ja) 2020-05-20
IL293587B2 (en) 2025-02-01
AU2022200527A1 (en) 2022-02-17
IL293587A (en) 2022-08-01
MX2020014089A (es) 2021-07-21
HUE056852T2 (hu) 2022-03-28
AU2022200527B9 (en) 2025-05-08
RU2016144724A (ru) 2018-05-18
NZ763587A (en) 2021-11-26
PT3132247T (pt) 2021-11-03
WO2015158868A2 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
SA521421882B1 (ar) نظم، وطرق وجهاز لتمديد مجموعة من الخلايا
EP4286055A3 (en) Analytical systems and methods for nucleic acid amplification using sample assigning parameters
CL2016001867A1 (es) Sistema y dispositivo para la generación de alto rendimiento de gotitas y métodos de uso combinatorios.
EP4345460A3 (en) Assay apparatuses, methods and reagents
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
MX384536B (es) Sistemas y metodos para multiples analisis.
EP4664110A3 (en) Diagnostic systems and methods
WO2014116851A3 (en) Methods and systems for using a cloud computing environment to share biological related data
GB2525104A (en) Massively parallel single cell analysis
WO2015200893A3 (en) Methods of analyzing nucleic acids from individual cells or cell populations
CA2873099C (en) Aptamer-based multiplexed assays
EA201692157A1 (ru) Синтез двухцепочечных нуклеиновых кислот
MX344792B (es) Sistemas y métodos para múltiples análisis.
EP4513175A3 (en) Optical systems and methods for biological analysis
AU2013252445A8 (en) Assays, methods and apparatus for assessing RNA disruption
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms
WO2015035239A3 (en) Reagents and methods for screening mps i, ii, iiia, iiib, iva, vi, and vii
MX2019000592A (es) Dispositivo dispensador de reactivos analiticos liquidos, y kits analiticos y metodos de uso relacionados.
MX2017001134A (es) Composiciones y metodos para la deteccion y analisis de tuberculosis micobacteriana.
EP3557259A3 (en) Methods and arrays for use in the same
BR112017002575A2 (pt) método para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo, kit e sistema para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo
MX2016017048A (es) Inmunoensayo reactivo y colaborativo potenciado por enzimas (ceer) usando citometria de flujo.
MY182547A (en) Polymerase chain reaction detection system
MX2018012485A (es) Sistemas y metodos para ensayos para trigliceridos electroquimicos.
MX2016016234A (es) Metodos, dispositivos y sistemas para analisis de muestras.